Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
复制标题
DOI：
10.1111/jgh.15336
复制
发表时间：
2021-07
影响因子：
4.1
通讯作者：
Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
中科院分区：
文献类型：
--
作者：
Hiraoka A;Kumada T;Kariyama K;Tada T;Tani J;Fukunishi S;Atsukawa M;Hirooka M;Tsuji K;Ishikawa T;Takaguchi K;Itobayashi E;Tajiri K;Shimada N;Shibata H;Ochi H;Kawata K;Yasuda S;Toyoda H;Ohama H;Nouso K;Tsutsui A;Nagano T;Itokawa N;Hayama K;Arai T;Imai M;Koizumi Y;Nakamura S;Joko K;Michitaka K;Hiasa Y;Kudo M;Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
本研究旨在阐明接受乐伐替尼治疗不可切除性肝细胞癌 (u-HCC) 的患者中肌肉体积减少（肌少症前期）的临床重要性。 2018 年 3 月至 2020 年 5 月期间，在日本特定机构接受乐伐替尼治疗的 437 名 u-HCC 患者中，有 151 名患者在引入乐伐替尼时拥有可用的计算机断层扫描成像数据。根据之前报道的临界值计算公式[第三腰椎中部水平的腰肌面积（cm2）/高度（m）2]诊断肌少症前期。通过逆概率加权回顾性研究了总生存期（OS）的临床特征和预后因素与肌少症前期的关系。 Cox 风险多变量分析显示甲胎蛋白 (≥400 ng/mL)（风险比 [HR] 2.271，P < 0.001）、巴塞罗那临床肝癌分期（C 和 D）（HR 1.625，P = 0.018）和肌少症前期阳性（HR 1.652，P = 0.042）是重要的预后因素。肌少症前期组 (n = 41) 的 OS 率比非肌少症前期组 (n = 110) 差（0.5 年、1 年和 1.5 年 OS 分别为 72.5%、27.9% 和 7.0% vs 80.7%、56.7% 和 46.1%； P < 0.001)，无进展生存期 (P = 0.025)。非肌少症前期组的停止乐伐替尼或疾病进展的时间更长（0.5 年、1 年和 1.5 年 OS：分别为 48.0%、24.5% 和 8.4% vs 20.0%、10.3% 和 4.2%；P < 0.001）。此外，在肌少症前期组中，不良事件食欲减退（任何级别）的频率更高（43.9% vs 18.2%，P = 0.003）。前肌少症被证明是接受乐伐替尼治疗 u-HCC 的患者的一个重要预后因素。
This study aimed to elucidate the clinical importance of muscle volume loss (pre‐sarcopenia) in patients receiving lenvatinib as treatment for unresectable hepatocellular carcinoma (u‐HCC). Of 437 u‐HCC patients treated with lenvatinib at specific institutions in Japan between March 2018 and May 2020, 151 with available computed tomography imaging data from the time of lenvatinib introduction were enrolled. Pre‐sarcopenia was diagnosed based on a previously reported cut‐off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm2)/height (m)2]. Clinical features and prognostic factors for overall survival (OS) with inverse probability weighting were investigated retrospectively for their relationship with pre‐sarcopenia. Cox hazard multivariate analysis showed alpha‐fetoprotein (≥400 ng/mL) (hazard ratio [HR] 2.271, P < 0.001), Barcelona Clinic Liver Cancer stage (C and D) (HR 1.625, P = 0.018), and positive for pre‐sarcopenia (HR 1.652, P = 0.042) to be significant prognostic factors. OS rates for the pre‐sarcopenia group (n = 41) were worse than those for the non‐pre‐sarcopenia group (n = 110) (0.5‐, 1‐, and 1.5‐year OS: 72.5%, 27.9%, and 7.0% vs 80.7%, 56.7%, and 46.1%, respectively; P < 0.001), as was progression‐free survival (P = 0.025). Time to stopping lenvatinib or disease progression was better in the non‐pre‐sarcopenia group (0.5‐, 1‐, and 1.5‐year OS: 48.0%, 24.5%, and 8.4% vs 20.0%, 10.3%, and 4.2%, respectively; P < 0.001). Also, the frequency of the adverse event appetite loss (any grade) was greater in the pre‐sarcopenia group (43.9% vs 18.2%, P = 0.003). Pre‐sarcopenia was shown to be a significant prognostic factor in patients treated with lenvatinib for u‐HCC.
登录
查看更多内容
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
6.3
作者：
Hiraoka A;Aibiki T;Okudaira T;Toshimori A;Kawamura T;Nakahara H;Suga Y;Azemoto N;Miyata H;Miyamoto Y;Ninomiya T;Hirooka M;Abe M;Matsuura B;Hiasa Y;Michitaka K
通讯作者：
Michitaka K
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
13.8
作者：
Hiraoka, Atsushi;Kumada, Takashi;Michitaka, Kojiro
通讯作者：
Michitaka, Kojiro